Zalutumumab in Non-curable Patients With SCCHN
NCT00542308
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
90
Enrollment
INDUSTRY
Sponsor class
Conditions
Head and Neck Cancer
Squamous Cell Cancer
Interventions
DRUG:
Zalutumumab
Sponsor
Genmab